<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972371</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-001</org_study_id>
    <nct_id>NCT03972371</nct_id>
  </id_info>
  <brief_title>The ProVerum First in Man PROVE Study</brief_title>
  <official_title>The ProVerum First in Man PROVE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProVerum Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProVerum Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical evaluation to assess the safety and performance of the ProVeeTM Urethral Expander
      System, designed to alleviate the symptoms of Benign Prostatic Hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, non-randomised, single centre, safety and feasibility study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Deployment of the Implant</measure>
    <time_frame>Immediately after the implant deployment procedure</time_frame>
    <description>Successful deployment of the implant from the delivery system in the target location within the prostatic urethra, as assessed with post deployment endoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion of the Implant</measure>
    <time_frame>Within 24 hours of the implant deployment procedure</time_frame>
    <description>Successful deployment of the implant from the delivery system in the target location within the prostatic urethra, as assessed with post deployment CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complications e.g. difficulty with urination, related to the implant use peri-procedurally and in the immediate follow up period</measure>
    <time_frame>Immediately after the implant deployment procedure, within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications e.g. pain, difficulty with urination, related to the implant throughout the follow-up period of 2 years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary assessment of the effectiveness of the procedure in alleviating LUTS voiding symptoms</measure>
    <time_frame>2 years</time_frame>
    <description>Change in symptom score using the Improvement in International Prostate Symptom Score and Quality of Life score instrument within the 2 year follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary assessment of the effectiveness of the procedure in improving urinary flow</measure>
    <time_frame>2 years</time_frame>
    <description>Change in Qmax measurement within the 2 year follow up period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ProVee Urethral Expander is implanted into the prostatic urethra to treat BPH symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The ProVee Urethral Expander System</intervention_name>
    <description>The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>The ProVee Expander</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males ≥ 50 years of age

          -  Moderate-to-severe symptomatic BPH

          -  IPSS of &gt; 15

          -  Peak urinary flow rate (Qmax) of &lt;12 mL/s

          -  Prostate volume of ≥ 30 and ≤80 cc

          -  Prostatic urethral lengths ≥ 4cm

        Exclusion Criteria:

          -  A prostatic urethral length of less than 4cm

          -  A prostatic volume &lt;30cc or &gt;80cc

          -  An obstructing intravesical prostatic median lobe

          -  Urinary incontinence due to an incompetent external sphincter

          -  Urethral pathologies that may prevent insertion of delivery system

          -  A current symptomatic urinary tract infection

          -  Current significant visible haematuria

          -  Patients with known allergy to nickel or titanium

          -  History of significant medical co-morbidity or prior surgery that may confound the
             results of the Study

          -  Another medical condition that would pose an unacceptable patient risk

          -  Known or suspected urological condition that may affected voiding function

          -  Neurogenic bladder and/or sphincter abnormalities

          -  Patients with cognitive disabilities unable to understand and give informed consent to
             the research study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

